RU-28306, also known as 4,α-methylene-N,N-dimethyltryptamine (4,α-methylene-DMT), is a synthetic indole alkaloid derivative which acts as a serotonin receptor agonist, with selectivity for 5-HT1 and 5-HT2 subtypes. It can be regarded as a conformationally restricted tricyclic derivative of DMT or a structurally simplified derivative of LSD. The binding affinity of racemic RU-28306 is closer to that of DMT than LSD, though with relatively higher affinity for 5-HT2 subtypes and lower for 5-HT1. Subsequent research has further described its activity at the serotonin 5-HT2A and 5-HT2C receptors. It has been sold as a designer drug and was first reported to the EMCDDA by a forensic laboratory in Slovenia in 2017. It was subsequently patented by Delix Therapeutics in 2021.
See also Partial lysergamide 6-MeO-RU-28306 RU-28251 RU-27849 Bay R 1531
References
External links RU-28306 - Isomer Design Hallucinogens You Probably Haven't Heard of: Tricyclic Tryptamines: Tricyclic Tryptamines - Nervewing - Blogger The Small & Handy RU-28306 Thread - Bluelight



